Amprenavir

Drugs

Volumn 55, Issue 6, 1998, Pages 837-842

  Adkins, J C ^a   Faulds, D ^a   Moyle, G ^a   Hughes, W T ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESISTANCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; META ANALYSIS; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; RASH; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031804689     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00015     Document Type: Article

References (27)

1. 1. G Moyle B Gazzard 1996 Current knowledge and future prospects for the use of HIV protease inhibitors Drugs 51 5 701 12 8861542 10.2165/00003495-199651050-00001 1:CAS:528:DyaK28XjsVehsbg%3D Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12
2. 2. Painter GR, St Clair MH, Demiranda P, et al. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94) [abstract]. Second National Conference on Human Retroviruses; 1995 Jan 29–Feb 2; Washington (DC), 167
3. 3. GR Painter S Ching D Reynolds 1996 141W 94 Drugs Future 21 4 347 50 1:CAS:528:DyaK2sXjtVWmsQ%3D%3D Painter GR, Ching S, Reynolds D, et al. 141W 94. Drugs Future 1996 Apr; 21(4): 347–50
4. 4. Sadler BM, Elkine M, Hanson C, et al. The safety and pharmacokinetics of 141W94: an HIV protease inhibitor [abstract]. Fifth International Conference on Clinical Aspects and Treatment of HIV Infection; 1995 Sep 26–29; Copenhagen
5. 5. BM Sadler C Rawls J Millard 1996 Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: a preliminary report [abstract] Antiviral Res 30 A42 Sadler BM, Rawls C, Millard J, et al. Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: a preliminary report [abstract]. Antiviral Res 1996 Apr; 30: A42
6. 6. MH St Clair J Millard J Rooney 1996 In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents Antiviral Res 29 53 6 8721545 10.1016/0166-3542(95)00916-7 1:STN:280:DyaK283otlOgtA%3D%3D St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996 Jan; 29: 53–6
7. 7. DJ Livingston S Pazhanisamy DJT Porter 1995 Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy J Infect Dis 172 1238 45 10.1093/infdis/172.5.1238 1:CAS:528:DyaK28XislOk Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995 Nov; 172: 1238–45
8. 8. JK Lazdins J Mestan G Goutte 1997 In vitro effect of α 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors J Infect Dis 175 1063 70 9129067 10.1086/520352 1:CAS:528:DyaK2sXjtVKgtbk%3D Lazdins JK, Mestan J, Goutte G, et al. In vitro effect of α 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997 May; 175: 1063–70
9. 9. JA Partaledis K Yamaguchi M Tisdale 1995 In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease J Virol 69 9 5228 35 7636964 1:CAS:528:DyaK2MXns1Kitr0%3D Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995 Sep; 69(9): 5228–35
10. 10. M Tisdale RE Myers B Maschera 1995 Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors Antimicrob Agents Chemother 39 8 1704 10 7486905 10.1128/AAC.39.8.1704 1:CAS:528:DyaK2MXnt1yhurc%3D Tisdale M, Myers RE, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995 Aug; 39(8): 1704–10
11. 11. Combinations therapies, third generation protease inhibitors are most effective to date against HIV (media release). Bioworld Today 1997 Jan 28; 8(18): 1–4
12. 12. M Nishiyama M Koishi M Fujioka 1996 Phase I clinical trial with a novel protease inhibitor for HIV, KVX-478, in healthy male volunteers [abstract] Antiviral Res 30 A35 Nishiyama M, Koishi M, Fujioka M, et al. Phase I clinical trial with a novel protease inhibitor for HIV, KVX-478, in healthy male volunteers [abstract]. Antiviral Res 1996 Apr; 30: A35
13. 13. Vertex Pharmaceuticals Incorporated. Press Release, Vertex 1996 May 23
14. 14. R Singh SY Chang LCE Taylor 1996 In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S 9 Rapid Commun Mass Spectrom 10 1019 26 8755234 10.1002/(SICI)1097-0231(19960715)10:9<1019::AID-RCM618>3.0.CO;2-J 1:CAS:528:DyaK28XksVWjtbY%3D Singh R, Chang SY, Taylor LCE.In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S 9. Rapid Commun Mass Spectrom 1996; 10: 1019–26
15. 15. Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract]. 37th ICAAC 1997 Sep 28–Oct 1; Toronto, 12
16. 16. DJ Kempf KC Marsh G Kumar 1997 Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir Antimicrob Agents Chemother 41 3 654 60 9056009 1:CAS:528:DyaK2sXhsFKnt7c%3D Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 Mar; 41(3): 654–60
17. 17. Polk RE, Israel DS, Pastor A, et al. Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers [abstract]. 37th ICAAC 1997 Sep 28–Oct 1; Toronto,12
18. 18. McDowell JA, Sadler BM, Millard J, et al. Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV-1-patients [abstract]. 37th ICAAC; 1997 Sep 28–Oct 1; Toronto, 13
19. 19. Ravitch JR, Walsh JS, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral abacavir (1592) in humans (poster no. 634). Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
20. 20. The 141W94 International Study Group. Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patients with 150 to 400 CD4+ cells/mm 3 [abstract]. 36th ICAAC; 1996 Sept 15–18; New Orleans, Louisiana, 8
21. 21. Bart P-A, Rizzardi GP, Gallant S, et al. Combination abacavir (1592)/amprenavir (141W94) therapy in HTV-1-infected antiretroviral-naive subjects with CD4+ counts >400 cells/ lL and viral load >5000 copies/mL (poster no. 365). Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
22. 22. Vertex Pharmaceuticals reports encouraging preliminary data from phase II clinical study with HIV protease inhibitor 141W94 (media release). Today’s News 1997 Oct 13; http://www.prnewswire.com
23. 23. Glaxo Wellcome’s quadruple HIV therapy. Scrip Mag 1997 Oct 24(2278): 22
24. 24. Double protease inhibitor regimens containing amprenavir show promise; investigational protease inhibitor amprenavir appears potent; well tolerated (media release). Today’s News 1998 Feb 2; http://www.prnewswire.com
25. 25. Investigational anti-HIV compound abacavir (1592) with individual HIV protease inhibitors results in potent antiretroviral activity (media release). Today’s News 1998 Feb 2; http://www.prnewswire.com
26. 26. Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs) [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
27. 27. Kost R, Cao Y, Vesanen M, et al. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV-1 [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago(IL)